Association of matrix metalloproteinase 3 and endogenous inhibitors with inflammatory markers in mitral valve disease and calcification
- PMID:30302620
- DOI: 10.1007/s11033-018-4372-8
Association of matrix metalloproteinase 3 and endogenous inhibitors with inflammatory markers in mitral valve disease and calcification
Abstract
Calcific mitral valve stenosis (MVS) is a common disease characterized by extensive remodeling of the extracellular matrix via matrix metalloproteinases (MMPs). The mechanism of calcification due to extensive matrix remodeling remains unclear. In this study, we investigated the relationship between MMP-3, tissue inhibitors of metalloproteinases (TIMPs) as well as pro-inflammatory cytokines and the phenomenon of calcification in MVS. 212 patients having rheumatic mitral stenosis (RMS) and 155 healthy control subjects were recruited in the Cardiology Department of La Rabta Hospital University. Levels of MMP-3, TIMPs, IL-6 and TNF-α were measured by ELISA sandwich assay, hs-CRP was measured by immunoturbidimetry. Plasma levels of MMP-3, TIMP-1 and MMP-3/TIMP-2 ratio were lower only in RMS women in comparison to the control group. Calcification degree correlated positively with MMP-3 in women and men. In addition, calcification was correlated positively with MMP-3/TIMPs ratio in women patients. The inflammatory parameters were positively associated with extracellular matrix turnover biomarkers in men patients. In patients, the level of MMP-3 was increased in men and women with a calcification score ≥ 5. In addition, MMP-3 level predicted the occurrence of calcification. At ROC curves analysis, the cut-off MMP-3 level was in women was 9.21 ng/ml (sensitivity 51.1%, specificity 89.3%) and in men was 12.84 ng/ml (sensitivity 78.6%, specificity 77.8%). The high levels of MMP-3 and the biomarkers of inflammation contribute to valvular remodeling and calcification of the mitral valve.
Keywords: Calcification; Inflammation; Matrix metalloproteinases; Mitral valve stenosis.
Similar articles
- Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation.Anné W, Willems R, Roskams T, Sergeant P, Herijgers P, Holemans P, Ector H, Heidbüchel H.Anné W, et al.Cardiovasc Res. 2005 Sep 1;67(4):655-66. doi: 10.1016/j.cardiores.2005.04.016.Cardiovasc Res. 2005.PMID:15913581
- Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis.Kaden JJ, Dempfle CE, Grobholz R, Fischer CS, Vocke DC, Kiliç R, Sarikoç A, Piñol R, Hagl S, Lang S, Brueckmann M, Borggrefe M.Kaden JJ, et al.Cardiovasc Pathol. 2005 Mar-Apr;14(2):80-7. doi: 10.1016/j.carpath.2005.01.002.Cardiovasc Pathol. 2005.PMID:15780799
- Late mitral restenosis after percutaneous commissurotomy: Predictive value of inflammation and extracellular matrix remodeling biomarkers.Mechmeche R, Zaroui A, Aloui S, Boukhris M, Allal-Elasmi M, Kaabachi N, Zouari B.Mechmeche R, et al.Heart Lung. 2017 Jul-Aug;46(4):258-264. doi: 10.1016/j.hrtlng.2017.03.006. Epub 2017 Apr 24.Heart Lung. 2017.PMID:28450150
- The role of matrix metalloproteinase 9 in fibrosis diseases and its molecular mechanisms.Wang Y, Jiao L, Qiang C, Chen C, Shen Z, Ding F, Lv L, Zhu T, Lu Y, Cui X.Wang Y, et al.Biomed Pharmacother. 2024 Feb;171:116116. doi: 10.1016/j.biopha.2023.116116. Epub 2024 Jan 5.Biomed Pharmacother. 2024.PMID:38181715Review.
- Targeting matrix metalloproteinases in inflammatory conditions.Clutterbuck AL, Asplin KE, Harris P, Allaway D, Mobasheri A.Clutterbuck AL, et al.Curr Drug Targets. 2009 Dec;10(12):1245-54. doi: 10.2174/138945009789753264.Curr Drug Targets. 2009.PMID:19909233Review.
Cited by
- Serotonin receptor type 2B activation augments TNF-α-induced matrix mineralization in murine valvular interstitial cells.Fong F, Xian J, Demer LL, Tintut Y.Fong F, et al.J Cell Biochem. 2021 Feb;122(2):249-258. doi: 10.1002/jcb.29847. Epub 2020 Sep 9.J Cell Biochem. 2021.PMID:32901992Free PMC article.
- Association of Matrix Metalloproteinases with Coronary Artery Calcification in Patients with CHD.Polonskaya YV, Kashtanova EV, Murashov IS, Striukova EV, Kurguzov AV, Stakhneva EM, Shramko VS, Maslatsov NA, Chernyavsky AM, Ragino YI.Polonskaya YV, et al.J Pers Med. 2021 Jun 3;11(6):506. doi: 10.3390/jpm11060506.J Pers Med. 2021.PMID:34205079Free PMC article.
References
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous